Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14666763 | 0.79 | ADH1B (0.38) | — | |
| SCHEMBL2491775 | 0.77 | SLC6A2 (0.41) | — | |
| SCHEMBL24439134 | 0.77 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL22822421 | 0.77 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL16081763 | 0.77 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL6490410 | 0.75 | BTK (0.35) | HSD11B1 | |
| SCHEMBL31249603 | 0.74 | SLC6A2 (0.51) | — | |
| SCHEMBL25250910 | 0.74 | SLC6A2 (0.51) | — | |
| SCHEMBL25298079 | 0.74 | SLC6A2 (0.51) | — | |
| SCHEMBL28406187 | 0.74 | USP30 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | HSD11B1 723/4885CHRM2 315/4885CHRM1 240/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | HSD11B1 723/4885CHRM2 315/4885CHRM1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.